We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

One such company is Intuitive Surgical ( ISRG 0.11%). The medical device specialist's market cap currently tops $215 billion, ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

J&J reported 4.3% top-line growth in 2024, or 7% growth at constant currencies and excluding covid vaccine sales. Assuming the Intra-Cellular acquisition closes in the second quarter, we think J&J ...

The institutional investor owned 43,167 shares of the company’s stock after purchasing an additional 2,058 shares during the period. Johnson & Johnson makes up approximately 1.6% of Ellsworth ...

Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a fifty day moving average price of $148.35 and a two-hundred day moving average price of $156.11.

Johnson & Johnson (JNJ ... were highlighted in the look-back and look-ahead on an earnings call, despite the company beating Wall Street expectations on revenue by $70 million and reporting ...